Blog

Silver Buck Advisory Board - Buccaneers &nbsp;&nbsp; Silver Buck is the UK's leading HealthTech PR and Digital Marketing agency. Silver Buck offers a diverse range of services covering PR, Digital Marketing, Social Media and Events for a range of clients looking to create awareness with NHS, Private Healthcare and Government audiences. &nbsp;&nbsp; Advisory board members are some of the most influential health IT, digital health and marketing individuals in the sector. Combined they are the force that is the Silver Buccaneers – pioneers, adventurers and visionaries. &nbsp;&nbsp; The advisory board members are Lloyd Price, Matt Hancock, Dr Lia Ali, Richard Corbridge, Dominic Cushnan, Sam Shah, Jon Hoeksma, Hassan Chaudhury, Rachel Murphy, Trishna Bharadia. &nbsp;&nbsp; <a data-mce-href="https://www.silver-buck.com" href="https://www.silver-buck.com" title="https://www.silver-buck.com" target="_blank" rel="noopener">https://www.silver-buck.com</a> &nbsp;&nbsp; Silver Buck&nbsp; &nbsp;&nbsp; Silver Buck specialise in crafting tailored strategies and campaigns designed to deliver targeted messages to the appropriate audiences, whether you’re a digital health start-up, B2C health app, NHS trust or a well-established health IT supplier. Our expertise ensures that the right messages reach the right individuals, from NHS CIOs and investors to patients. &nbsp;&nbsp; At Silver Buck, we tell it like it is, we listen to your unique challenges and goals, we hit the ground running and we have proven results. We’re highly flexible and agile in our approach, accommodating to the changing needs of growing companies.. &nbsp;&nbsp; Healthcare demands a different perspective and creative solutions balanced with subtle nuances that often only the healthcare community understand. We aspired to be the leading full-service agency that had walked in your shoes, understood your challenges and had the experience that meant we knew exactly how to solve them. &nbsp;&nbsp; From our foundations in strategic health teach PR, our multi-skilled agency team has grown to include renowned journalists, expert communicators, digital marketing specialists, branding gurus, and creative content creators. However, Silver Buck as an agency has always been synonymous with digital health PR.

Nelson Advisors joins HealthTech Advisory Board alongside Former Secretary of State for Health & Social Care  and Senior NHS England staff

Businessman holding medical icon for health insurance concept

There are several key differences in MedTech M&amp;A between Europe and the USA, primarily related to regulatory frameworks, deal structures and market dynamics.Regulatory Differences &nbsp;USA: The Food and Drug Administration (FDA) is a centralized authority with a predictable, though rigorous, regulatory pathway. The FDA has actively tried to make the U.S. an attractive market for new medical devices, particularly for innovative technologies like AI-enabled devices.&nbsp; &nbsp; Europe: The regulatory landscape in Europe has become more complex with the introduction of the EU Medical Device Regulation (MDR) in 2021. The MDR replaced the previous Medical Device Directive (MDD), making the approval process stricter, requiring more clinical data, and extending time-to-market. This has led some companies to prioritise U.S. market entry over Europe.Deal Structure Differences Purchase Price Adjustments: In the U.S., purchase price adjustments (PPAs) are almost universal, with buyers expecting to be compensated for shortfalls in working capital or cash. In Europe, "lock box" structures are more common, especially in competitive auctions.Earn-outs: While common in both markets, the metrics used for earn-outs differ. In the U.S., revenue-based earn-outs are more prevalent, whereas in Europe, EBIT/EBITDA is the preferred metric. Liability Caps: U.S. deals often have lower seller liability caps (10% or less of the purchase price), largely due to the widespread use of representations and warranties (R&amp;W) insurance. In Europe, liability caps are typically higher (25% to 50%), as sellers are more accustomed to bearing more risk, although R&amp;W insurance is becoming more common.Material Adverse Change (MAC) Clauses: MAC clauses are standard in nearly all U.S. deals, allowing a buyer to back out if the target company experiences a significant negative change between signing and closing. These clauses are rare in Europe.Dispute Resolution: In the U.S., litigation is the default for dispute resolution. In Europe, arbitration is much more common, particularly in cross-border transactions.Market Dynamics Profitability: U.S.-based MedTech companies generally have higher operating margins than their European peers. This is largely attributed to better access to the lucrative U.S. market, where medical device prices are typically higher due to a different healthcare system. Market Fragmentation: The European MedTech market is more fragmented, with a large number of small and medium-sized companies. In contrast, the U.S. market is larger and less fragmented. This can impact the scale of acquisitions and the types of companies being targeted.To discuss how Nelson Advisors can help your Healthtech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Key MedTech Merger and Acquisition differences between Europe and the USA

The most sophisticated AI model is worthless if it cannot seamlessly integrate into the complex, manual, and often chaotic workflows of a healthcare organisation. Owning the workflow means moving from being a standalone "tool" to an embedded, indispensable component of a daily process. This is the central argument of the new healthcare AI economy. "AI's value is not in its existence but in its application within a functional, human-centric system. This approach is evident in both administrative and clinical applications." &nbsp; In the administrative domain, AI-powered solutions are directly addressing the operational burdens that plague healthcare organisations, which are a major contributor to staff burnout.Clinical documentation and scribing provide a prime example. The startup Abridge has mastered this workflow by using an AI platform that listens to patient-provider conversations and automatically generates medically relevant summaries for care teams and patients. This solution directly addresses the administrative burden that leads to burnout, providing a tangible value proposition: Abridge has saved providers an average of two hours per day. &nbsp;&nbsp; Similarly, the GenAI-native platform Arintra automates medical coding from patient charts, which demonstrably reduces errors and claim denials. At a single health system, its implementation led to a 5.1% revenue increase and a 43% drop in claim denials, while cutting coding costs by about one-third. &nbsp; In clinical workflows, AI is being integrated to enhance, not replace, human expertise. In radiology, for example, AI platforms can analyse medical images and prioritise work lists based on suspected pathologies, ensuring that urgent cases receive timely attention. This automation enhances efficiency and diagnostic accuracy by integrating directly with radiology information systems and picture archiving and communication systems (RIS/PACS).In a published study in the Journal of the American Medical Association, an AI system achieved a diagnostic accuracy rate of 94% in detecting lung nodules, significantly outperforming human radiologists. Robot-assisted surgery, which captured the largest market share in 2024, demonstrates how AI improves surgical precision, leading to better patient outcomes and quicker recovery times.To discuss Healthcare AI and how Nelson Advisors can help your Healthtech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Healthcare AI: Beyond the Algorithm

Nelson Advisors Partner Lloyd Price invited to Judge the 'Digital Health Hub Foundation: Digital Health Awards 2025' at HLTH Event in Las Vegas in October 2025.The Digital Health Hub Foundation Awards @ HLTH spotlight the most innovative health tech companies transforming healthcare through technology. In 2025, we’re back with innovation-targeted categories, recognising the companies making the biggest impact. &nbsp;&nbsp; Each year, the competition attracts groundbreaking companies from around the world, with only the most impactful advancing to the final stage. Join us on this journey to explore new innovations and spotlight the most impactful companies transforming digital health."Our distinguished panel of judges, featuring top names from healthcare, AI, venture capital, and innovation, will soon begin the rigorous evaluation process to determine the quarterfinalists. "<a data-mce-href="https://www.digitalhealthhub.org/awards/2025/digital-health-awards" href="https://www.digitalhealthhub.org/awards/2025/digital-health-awards" title="https://www.digitalhealthhub.org/awards/2025/digital-health-awards" target="_blank" rel="noopener">https://www.digitalhealthhub.org/awards/2025/digital-health-awards﻿</a>

Nelson Advisors to Judge the 'Digital Health Hub Foundation Awards’ at HLTH 2025

Nelson Advisors partners Lloyd Price and Paul Hemings will judge the Fast Pitch Awards at the Healthcare Summit 2025.&nbsp;Introducing the Health Tech Stream &nbsp; An exclusive track spotlighting transformative technologies, next-gen solutions, and early-to-growth stage ventures across: &nbsp;&nbsp; AI diagnostics Digital therapeutics Med tech &amp; devices Remote care platforms Data &amp; predictive analyticsHealthcare Summit 2025 &nbsp;&nbsp; The Healthcare Summit is attended by 1,000+ operators, investors and advisors across the health and social care sector.The Healthcare Summit 2025 is run by HealthInvestor UK, part of Nexus Media Group, a leading B2B publishing and events company that focuses on various sectors, including health, social care, seniors housing, education, early years, and property. HealthInvestor UK is one of Nexus Media Group's key publications, offering news, market analysis, and events for the UK healthcare sector.<a data-mce-href="https://healthcare-summit.co.uk" href="https://healthcare-summit.co.uk" title="https://healthcare-summit.co.uk" target="_blank" rel="noopener">https://healthcare-summit.co.uk</a>

Nelson Advisors partners invited to judge the Fast Pitch Awards at the Healthcare Summit 2025

The MedTech mergers and acquisitions (M&amp;A) landscape is undergoing a profound and irreversible transformation. The traditional playbook, which long emphasised incremental product improvements and narrowly focused acquisitions, has become largely obsolete. A new era has emerged, defined by the strategic convergence of medical technology, data intelligence, and consumer-centric care models.&nbsp; &nbsp;&nbsp; Current market dynamics reflect a "flight to quality," with a clear trend toward fewer but larger, high-value deals. The primary drivers of this deal flow are no longer just new devices, but increasingly AI-powered solutions, digital health platforms, and assets that facilitate personalised medicine and direct-to-consumer (D2C) engagement. Value is now intrinsically linked to intellectual property that creates a "competitive moat", business models that generate predictable, recurring revenue from services and data, and operational efficiencies enabled by AI and automation. &nbsp; Navigating this new paradigm requires a heightened level of due diligence. It is no longer sufficient to merely audit financials and legal documents; a thorough assessment of a target's regulatory risk profile, particularly in light of stringent new frameworks like the European Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), is a critical imperative. Similarly, a comprehensive evaluation of the true value and defensibility of a target's IP portfolio is essential. To mitigate risk and bridge valuation gaps in an uncertain economic climate, acquirers are increasingly adopting alternative deal structures, such as earn-outs and licensing agreements.&nbsp; &nbsp;&nbsp; Looking ahead, the competitive landscape is being fundamentally reshaped by cross-sector convergence, with major technology and retail firms building holistic healthcare ecosystems. This is creating a bifurcated market where MedTech companies must either make large, transformative bets or pursue a disciplined "string-of-pearls" strategy with smaller, highly focused acquisitions.To discuss any of these points and how Nelson Advisors can help your MedTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

Nelson Advisors joins HealthTech Advisory Board alongside...

Key MedTech Merger and Acquisition differences between Eu...

Healthcare AI: Beyond the Algorithm

Nelson Advisors to Judge the 'Digital Health Hub Foundati...

Nelson Advisors partners invited to judge the Fast Pitch ...

The Strategic Convergence of MedTech, Technology and Data